EHMT1/2-LIG1 axis enhances Temozolomide Sensitivity in Experimental Glioma

Clicks: 8
ID: 337528
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #137 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Temozolomide (TMZ) is a standard treatment for glioblastoma. The efficacy is limited by acquired resistance, particularly in tumors with an unmethylated MGMT promoter. Identifying synthetic lethal interactions may inform future therapeutic strategies. Methods We performed genome-wide CRISPR-Cas9 knockout screens in MGMT-expressing glioma cell lines under TMZ treatment. Candidate hits were validated by genetic depletion and pharmacological inhibition and assessed in publicly available datasets. Mechanistic investigation included RNA-seq, immunoblotting and immunofluorescence. Therapeutic efficacy was evaluated in patient-derived glioblastoma cultures and an orthotopic xenograft glioma model. Results CRISPR screening identified euchromatic histone-lysine N-methyltransferases (EHMT1/EHMT2) and DNA Ligase 1 (LIG1) as synthetic lethal interactors of TMZ. Their expression is associated with overall survival in publicly available glioma datasets. Genetic depletion of EHMT1, EHMT2 and LIG1 enhanced TMZ sensitivity and increased DNA damage. Pharmacological EHMT1/2 inhibition using UNC0642 demonstrated robust synergism with TMZ across multiple glioma cell lines and patient-derived primary cultures. Transcriptomic profiling revealed rapid DNA mismatch repair (MMR) pathway induction upon TMZ, whereas synthetic lethal interactors were not consistently upregulated. Combined TMZ and UNC0642 treatment disrupted the EHMT1/2-LIG1K126-UHRF1-DNMT1 DNA methylation maintenance axis, resulting in enhanced DNA damage. In an orthotopic xenograft model, combination therapy prolonged survival compared to monotherapies in late treatment intervals. Conclusion We discovered and validated EHMT1/2 and LIG1 as actionable targets synergizing with TMZ through disruption of the DNA methylation maintenance pathway. These data provide a preclinical rationale for the investigation of EHMT1/2 inhibitors in combination with TMZ, particularly for MGMT-unmethylated glioblastoma.
Reference Key
openalex_W7224091779 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jil Trampert, Lara Annina Haeusser, Hannes Becker, Laurence Kuhlburger, Marcello Zago, Foteini Tsiami, Bianca Walter, Marko Maric, Nihal Olcay Dogan, Surender Surender, Louise Maise, Nicolas Casadei, Manfred Claassen, Sven Nahnsen, Jens Schittenhelm, Marcos Soares Tatagiba, Susanne Beck, Daniel Josef Merk, Ghazaleh Tabatabai
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag271
URL
https://doi.org/10.1093/noajnl/vdag271
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.